Rising R&D Activities to Treat Musculoskeletal disorders (MSD) is Emanating the Market Growth

Musculoskeletal disorders (MSD) are injuries or disorders of the muscles, nerves, tendons, joints, cartilage, and spinal discs. The Department of Labor's Bureau of Labor Statistics defines MSDs as a musculoskeletal system and connective tissue diseases and disorders when the exposure or event that caused the condition was repetitive motion, overexertion, or bodily reaction such as bending, climbing, crawling, reaching, or twisting. Sports-related injuries, musculoskeletal disorders, and age-related dysfunction are all linked. Back discomfort, rheumatoid arthritis, and other musculoskeletal conditions are among the most prevalent. The market is growing with the continuous growth in the geriatric population and change in the lifestyle habits of the leading to bad posture, which is increasing the prevalence of musculoskeletal system disorders.

According to Marketlook Consulting’s research report “Global Musculoskeletal Diseases Market Analysis, 2022”, the Global Musculoskeletal Diseases market is anticipated to grow at a CAGR of 5.7% during 2023-30 The market would reach USD 6.9 Bn by 2030.

Based on type, rheumatoid arthritis grabbed a significant market share. The growth factor for RA globally can be measured by several factors, including the prevalence and incidence rates, as well as the economic burden of the disease. According to the Global Burden of Disease Study 2019, the global prevalence of RA was estimated to be around 415 million people, which is about 4.4% of the world's population. The incidence rate of RA varies across regions, with higher rates reported in developed countries. For example, in the United States, the annual incidence rate of RA is approximately 41 cases per 100,000 persons.     

Based on the distribution channel, the Hospitals segment held a dominant market share in the year 2021. This is the result of growing number of hospitals chain and better healthcare infrastructure all over the world. Also, a budding number of specialty orthopedic hospitals assist the growth of the market. The U.S News and World Report Assessed 1660 hospitals for with Hospitals for special surgery. Such a mounting number of specialty hospitals and increasing spending on health care infrastructure drive the growth of the Musculoskeletal Disease market share.

High cost of the treatment is a restraining factor for the market. Drugs associated with the treatment of musculoskeletal disorders are expensive, rendering them unaffordable for a large segment of society, especially in underdeveloped or developing economies. There is also a significant gap between the demand and supply of necessary healthcare infrastructure which means that quality healthcare remains inaccessible to the majority of the global population.

“Global Musculoskeletal Diseases Market Analysis, 2022” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for Musculoskeletal Diseases providers across the Globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.      

Asia Pacific Dominated the Market

Based on Leading regions, Asia Pacific dominated the global Musculoskeletal Diseases market in 2022 and is projected to maintain its dominance during the forecasted period 2023-30 due to the Geographical analysis is an essential component of the report’s research and development study for market analysis. The regional extent section contains crucial insights into market sales growth at both regional and country levels. This market scope’s geographical spectrum analyses and investigates each regional spectrum of the Musculoskeletal Diseases Market industry. Each of these major regions is analyzed based on manufacturing, supply, statistics, and import & export. Furthermore, surge in the number of people affilicted with musculoskeletal system disorders due to bad posture brought on by lifestyle changes, aging, and geriatric predisposition. This further adds to the growth of this region in the global Musculoskeletal Diseases industry as stated in Marketlook Consulting research report “Global Musculoskeletal Diseases Market Analysis, 2022”.

According to Marketlook Consulting’, the key players with a considerable market share in the global Musculoskeletal Diseases market are Bayer AG, Pfizer Inc., Sanofi, Zyla Life Sciences, Novartis AG, Johnson & Johnson Services, Inc., Merch & Co., Inc., Eli Lilly and Company, Abbott, ABIOGEN PHARMA S.p.A., Ampio Pharmaceuticals Inc. apart from others.

Market Segmentation:

1.By Type Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Others

2. By Treatment Type Medication, Surgery, Therapy

3. By Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3. By Region North America, Europe, Asia-Pacific, Latin America, Middle East and Africa

6. By Company Bayer AG, Pfizer Inc., Sanofi, Zyla Life Sciences, Novartis AG, Johnson & Johnson Services, Inc., Merch & Co., Inc., Eli Lilly and Company, Abbott, ABIOGEN PHARMA S.p.A., Ampio Pharmaceuticals Inc. apart from others.

Key questions answered in the study:

1. What are the current and future trends of the Musculoskeletal Diseases industry?
2. How the industry has been evolving in terms of consumer type demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Musculoskeletal Diseases industry?
5. What is the customer orientation, purchase behaviour, and expectations from the Musculoskeletal Diseases firms across various regions?